BENF

Beneficient is not a going-concern-safe business at these numbers, it is a balance sheet in the process of unwinding. Reported FY2026 revenue is NEGATIVE $39.1M — a contra-revenue figure driven by the consolidation of the Customer ExAlt Trusts, where ExAlt Loan interest/fee income and provisions for credit losses net against each other and flip the top line negative. When 'revenue' can print below zero, standard valuation (the -6.3x P/S here) is meaningless; the $246M market cap is a bet on a business model, not on earnings. Operating income was -$167M, net income -$87.4M, and the accumulated deficit sits at -$2.10B. Stockholders' equity is NEGATIVE $189M against $338M of liabilities (a -1.78x liabilities/equity ratio), so common holders are structurally underwater on the books.

The liquidity picture is the sharpest red flag. Cash and equivalents total just $2.54M while operating cash flow was -$38.7M for the year — roughly a month of runway at the FY2026 burn rate absent new financing. The company's history shows it repeatedly funds the ExAlt Trusts by issuing Class A common or convertible preferred as consideration for capital calls, which points to continued, potentially severe dilution ahead as the primary escape valve. The one 'good' year (FY2025 net income +$51.2M on -$7.9M revenue) was itself an artifact of non-operating marks, not durable earnings — the five-year history (revenue swinging from +$55.3M in FY2021 to negative in FY2023–FY2026; a -$2.10B net loss in FY2024) shows no stable, cash-generative core.